Canadian Journal of Gastroenterology and Hepatology / 2019 / Article / Tab 4

Research Article

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy

Table 4

Patients with known RAS testing.

PatientPrimary therapyRAS testingSecondary therapySVR

1OBV/PTV/r+DSV+RBV
12 weeks
not detectedLDV/SOF+RBV
12 weeks
NO

5OBV/PTV/r+DSV
4 weeks
not detectedLDV/SOF
12 weeks
YES

7OBV/PTV/r+DSV
1 week
not detectedLDV/SOF
12 weeks
YES

15SOF+RBV
24 weeks
not detectedSOF+DCV 12 weeks →SOF+RBV 12 weeksYES

20LDV/SOF
8 weeks
not detectedGZR/EBR+RBV
16 weeks
YES

23ASV+DCV
24 weeks
NS5A: L31V, Y93H
NS3: S122R, D168E
OBV/PTV/r+DSV+RBV
12 weeks
NO

25ASV+DCV
24 weeks
NS5A - Y93Y/HLDV/SOF+RBV
24 weeks
YES

28OBV/PTV/r+DSV+RBV
4 weeks
not detectedLDV/SOF
24 weeks
YES

29OBV/PTV/r+DSV+RBV
12 weeks
not detectedLDV/SOF
24 weeks
YES

30OBV/PTV/r+DSV+RBV
12 weeks
NS3-170ILDV/SOF
24 weeks
YES

31ASV+DCV
24 weeks
NS5A: 31V, 93HOBV/PTV/r+DSV+RBV
12 weeks
YES

RAS: resistance associated substitution; OBV: ombitasvir; PTV: paritaprevir; DSV: dasabuvir; RBV: ribavirin; LDV: ledipasvir; SOF: sofosbuvir; ASV: asunaprevir; DCV: daclatasvir.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.